Resectable Non-Small Cell Lung Cancer

Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary ResultsПодробнее

STS Webinar: The Evolving Role of Radiation Therapy in Resectable Lung CancerПодробнее

Treating resectable non-small-cell lung cancerПодробнее

AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung CancerПодробнее

The impact of durvalumab for resectable non-small cell lung cancerПодробнее

Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC?Подробнее

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLCПодробнее

Integrating Immunotherapy in Resectable NSCLCПодробнее

Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary ResultsПодробнее

Reinforcing Precision Tactics in Genomically Altered Resectable NSCLCПодробнее

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung CancerПодробнее

July 25, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)Подробнее

Adherence & outcomes of neoadjuvant immunotherapy in resectable NSCLCПодробнее

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLCПодробнее

The future of chemo-immunotherapy in resectable non-small cell lung cancerПодробнее

Immunotherapy for early-stage, resectable NSCLC: From clinical trial data to guidelinesПодробнее

Dr Heymach on Updated AEGEAN Data in Resectable NSCLCПодробнее

Outcomes and pCR after chemo-immunotherapy in resectable NSCLCПодробнее

IASLC 2024 World Conference on Lung Cancer: Dr. Singhi Discusses Highly Anticipated SessionsПодробнее

How to Treat Early Stage Non-Small Cell Lung CancerПодробнее